Anthem Biosciences Ltd. (ANTHEM): Anthem Biosciences Share Price Rises 3.03% Today; Valuation and Peer Context in Focus
- September 1, 2026
- Posted by: Harsh Piplani
- Category: News
Anthem Biosciences Share Price today is Rs 918.55, up Rs 27.05 or 3.03% from Rs 891.50. The stock opened at Rs 898, touched Rs 919.95, slipped to Rs 896, and recorded turnover of Rs 0.51 crore. Market capitalisation stood at Rs 50,740.53 crore.
The supplied data confirms a same-day price rise but does not identify a company-specific trigger. That distinction matters: the move is verified, while the cause is unconfirmed in the available dataset.
Anthem Biosciences Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 918.55 |
| Previous Close | Rs 891.5 |
| Today's Move | Rs 27.05 (+3.03%) |
| Open | Rs 898 |
| High | Rs 919.95 |
| Low | Rs 896 |
| Turnover | Rs 0.51 crore |
| Market Capitalisation | Rs 50,740.53 crore |
| Market Cap Category | Large Cap |
Anthem Biosciences Ltd. (ANTHEM) rose to Rs 918.55 from the previous close of Rs 891.5, a move of Rs 27.05 or 3.03%. The stock opened at Rs 898, reached a high of Rs 919.95, recorded a low of Rs 896.
Anthem Biosciences Share Price moved higher through the session after opening above the previous close. At Rs 918.55, the stock was close to its intraday high of Rs 919.95 and well above the day low of Rs 896. Against the previous close of Rs 891.50, the gain was Rs 27.05 or 3.03%.
This intraday setup points to firm buying interest within the day’s range of Rs 896 to Rs 919.95. Turnover of Rs 0.51 crore adds trading context, but it does not by itself explain the move. Based on the event tag, the confirmed takeaway is simple: Anthem Biosciences Share Price was among stocks rising today.
Anthem Biosciences Ltd. (ANTHEM) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 50,740.53 crore |
| P/E Ratio | 87.21x |
| P/B Ratio | 16.05x |
| ROE | 21.98% |
| ROCE | 29.62% |
| EPS | Rs 10.22 |
| Book Value Per Share | Rs 55.55 |
| Dividend Yield | 0.22% |
Anthem Biosciences Ltd. (ANTHEM) fundamental metrics show P/E 87.21x, P/B 16.05x, ROE 21.98%, ROCE 29.62%. These figures provide context only and are not a buy or sell signal.
Anthem Biosciences Ltd. has a market capitalisation of Rs 50740.53 crore and falls in the Large Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 87.21x, P/B at 16.05x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 21.98% and ROCE of 29.62%, helping investors compare shareholder returns and capital efficiency. Additional supplied metrics include EPS of Rs 10.22, book value per share of Rs 55.55, dividend yield of 0.22%, adding context to earnings, balance-sheet value and historical payout. Against the supplied same industry benchmark, these figures can be compared with benchmark median P/E of 30.92x, median ROE of 11.81%, median ROCE of 13.65%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 87.21x |
| Benchmark Median P/E | 30.92x |
| Benchmark Average P/E | 48.02x |
| Benchmark P/E Range | 3.87x to 667.16x |
| Company P/B Ratio | 16.05x |
| Benchmark Median P/B | 2.88x |
| Company ROE | 21.98% |
| Benchmark Median ROE | 11.81% |
| Company ROCE | 29.62% |
| Benchmark Median ROCE | 13.65% |
| Company Market Capitalisation | Rs 50,740.53 crore |
| Benchmark Median Market Cap | Rs 683.05 crore |
Anthem Biosciences Ltd. (ANTHEM) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.
Anthem Biosciences Ltd. (ANTHEM) has a P/E ratio of 87.21x, which is above the benchmark median of 30.92x, a difference of +182.05%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Anthem Biosciences Ltd. (ANTHEM) has a ROE of 21.98%, which is above the benchmark median of 11.81%, a difference of +86.11%. Anthem Biosciences Ltd. (ANTHEM) has a ROCE of 29.62%, which is above the benchmark median of 13.65%, a difference of +117%.
Track stocks leading today through the Univest top gainers screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | SUNPHARMA | 4,60,696.31 | 38.8 | 5.43 | 14.85 | 19.11 |
| Divi's Laboratories Ltd. | DIVISLAB | 2,46,062.83 | 83.91 | 13.89 | 16.19 | 21.51 |
| Torrent Pharmaceuticals Ltd. | TORNTPHARM | 1,91,515.22 | 86.82 | 21.1 | 26.76 | 19.27 |
| Zydus Lifesciences Ltd. | ZYDUSLIFE | 1,18,403.7 | 25.69 | 4.3 | 19.69 | 21.39 |
| Cipla Ltd. | CIPLA | 1,14,554.33 | 33.94 | 3.25 | 11.83 | 16 |
Anthem Biosciences Ltd. (ANTHEM) has a P/E ratio of 87.21x compared with the displayed peer median of 38.8x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 21.98% compares with a peer median of 16.19% across the companies shown in the table. ROCE stood at 29.62% versus the displayed peer median of 19.27%, providing a capital-efficiency comparison. Anthem Biosciences Ltd. (ANTHEM) has a market capitalisation of Rs 50,740.53 crore. Among the 5 peers shown, 5 have a larger market capitalisation.
Why Investors Are Watching Anthem Biosciences
- Verified move: the stock rose Rs 27.05 or 3.03% to Rs 918.55 from Rs 891.50.
- Near day high: it traded close to Rs 919.95 after opening at Rs 898.
- Premium valuation: P/E 87.21 and P/B 16.05 are above industry medians.
- Strong returns: ROE 21.98% and ROCE 29.62% exceed industry medians.
- Useful peer contrast: profitability compares well with several larger pharma names.
About Anthem Biosciences
Based on supplied data, Anthem Biosciences Ltd. sits in Healthcare under Pharmaceuticals & Drugs. Within the same-industry benchmark of 200 companies, its Rs 50,740.53 crore market cap is much larger than the median company, though still below major listed peers such as Sun Pharma, Divi’s Laboratories, Torrent Pharmaceuticals, Zydus Lifesciences and Cipla.
That positioning helps explain why Anthem Biosciences Share Price is being watched today: it combines large listed scale, premium valuation and strong return ratios within a closely tracked pharma universe.
Track Anthem Biosciences Share Price on Univest
Use Anthem Biosciences Ltd. (ANTHEM) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top-gainers lists and related market analysis.
Use the Anthem Biosciences Ltd. (ANTHEM) live share-price page, the Univest top gainers screener, and Univest market blogs to follow live price moves, valuation ratios, profitability metrics and broader market context.
For readers tracking Anthem Biosciences Share Price Today, the key point is that the stock’s rise is confirmed by market data, while any specific reason behind the move is not confirmed in the supplied dataset.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Why is Anthem Biosciences Share Price rising today?
Ans. Anthem Biosciences Share Price rose 3.03% to Rs 918.55 from the previous close of Rs 891.50. The supplied data confirms the rise, but it does not establish a company-specific catalyst.
What is Anthem Biosciences Share Price Today?
Ans. Anthem Biosciences Share Price Today is Rs 918.55. The stock opened at Rs 898, traded between Rs 896 and Rs 919.95, and was up Rs 27.05 on the day. The previous close was Rs 891.5.
Is Anthem Biosciences expensive on valuation metrics?
Ans. On the supplied data, the stock trades at P/E 87.21 and P/B 16.05, both above the same-industry median values of 30.92 and 2.88. The company trades at a P/E ratio of 87.21x.
How profitable is Anthem Biosciences compared with its industry?
Ans. ROE is 21.98% versus the industry median of 11.81%, and ROCE is 29.62% versus the median of 13.65%, indicating stronger profitability than benchmark central levels. The stock belongs to the Healthcare sector.
How does Anthem Biosciences compare with major pharma peers?
Ans. Anthem has a smaller market cap than the 5 displayed peers, but its ROCE of 29.62% is higher than Sun Pharma, Divi’s, Torrent, Zydus and Cipla. Its P/E of 87.21 is close to Divi’s 83.91 and Torrent’s 86.82.
